Mechanistic description
A plausible upstream submechanism is that lipid-poor APOE4 disrupts ABCA1 trafficking, likely via ARF6-associated endosomal retention, reducing cholesterol efflux and mature apoE lipidation. This may create a state where extracellular lipid export is impaired and ER-accessible cholesterol remains insufficient for stable SCAP-INSIG retention, but that final ER-sensing link remains inferential.
Evidence for (8)
APOE4 is associated with ABCA1 mistrafficking, impaired recycling, and reduced cholesterol efflux in astrocytic systems.
LXR-ABCA1 axis rescue improves ApoE4-related glial lipid phenotypes and supports an upstream lipidation strategy.
Preclinical ApoE4/tau systems show benefit from enhancing ABCA1/ApoE lipidation biology.
APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes.
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation.
APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types.
Cell type-specific roles of APOE4 in Alzheimer disease.
APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints.
Evidence against (3)
No cited study directly shows that correcting ABCA1 trafficking restores ER cholesterol, SCAP-INSIG binding, or SREBP2 processing.
ABCA1 defects may primarily affect extracellular apoE particle quality and amyloid handling rather than ER sterol sensing.
LXR/ABCA1-directed therapies face chronic peripheral lipogenesis and hepatic liability concerns.
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 1 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.